HRTX - Shares of Heron Therapeutics Inc. (HRTX) Exceed 52-Week High
Heron Therapeutics Inc. (NASDAQ:HRTX) traded today at a new 52-week high of $42.80. Approximately 85.4 million shares have changed hands today, as compared to an average 30-day volume of 2.8 million shares.
Based on a current price of $6.09, Heron Therapeutics Inc. is currently 0.7% above its average consensus analyst price target of $6.05.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of SUSTOL, ZYNRELEF, and CINVANTI. Its pipeline product is HTX-011.
In the past 52 weeks, shares of Heron Therapeutics Inc. have traded between a low of $4.58 and a high of $42.80 and is now at $6.09, which is 33% above that low price.
Receive IBN Spotlights - "Bite Size" Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About IBN (InvestorBrandNetwork)
IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.
For more information on IBN, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer